Related Experiment Videos
Technology evaluation: ISIS-3521
Abstract:
It is well known that the PKC family of enzymes is involved in the propagation of intracellular signals and is implicated in cancers, inflammatory processes, cardiovascular and endocrinological diseases. Relatively low isozyme specificity has largely limited the clinical use of PKC antagonists. The members of the PKC family differ from each other at the mRNA level and the selectivity of antisense compounds is distinguished by this feature. According to ISIS Pharmaceuticals Inc antisense compounds are highly selective inhibitors even within a family of closely-related genes [321211]. The use of these compounds could be invaluable as tools to discover the mechanisms and roles of specific PKC isozyme in normal and diseased tissues and could provide the information for better cancer treatments [226799]. The isozyme of PKC-alpha is believed to play an important role in the proliferation of several types of cancer cells [234471-323703]. Recently, ISIS Pharmaceuticals received a patent US-05885970, covering the antisense technique targeting human PKC-alpha for cancer therapy (US-0588970). In the past few years, several effective antisense oligonucleotides (AS ONs) targeting murine and human PKC-alpha isozymes have been developed and a series of positive results have been obtained in cell culture and in nude mice cancer transplantation [327453]. Phase I clinical trials have shown that relatively high doses were well tolerated with no obvious side-effects [226799]. Whether these AS ONs are beneficial to patients suffering from cancer, either alone or in combination with other chemotherapy drugs is still under evaluation in a clinical setting.
Insights
Antisense oligonucleotides (AS ONs) show promise for cancer therapy by selectively inhibiting Protein Kinase C-alpha (PKC-alpha). Early clinical trials indicate good tolerance, with ongoing evaluation for efficacy in cancer treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Protein Kinase C (PKC) enzymes are crucial for intracellular signaling and implicated in various diseases, including cancer.
- Limited isozyme specificity of traditional PKC antagonists hinders clinical application.
- PKC-alpha isozyme is specifically linked to the proliferation of several cancer cell types.
Purpose of the Study:
- To explore the potential of antisense oligonucleotides (AS ONs) as selective inhibitors of PKC isozymes for cancer therapy.
- To investigate the efficacy and safety of AS ONs targeting PKC-alpha.
Main Methods:
- Development of AS ONs targeting specific PKC-alpha mRNA.
- Testing AS ON efficacy in cell cultures and animal cancer models.
- Conducting Phase I clinical trials to assess safety and tolerability.
Main Results:
- AS ONs demonstrate high selectivity for PKC isozymes, even within closely related gene families.
- Positive results observed in preclinical cancer models (cell culture and xenografts).
- Phase I clinical trials showed AS ONs were well-tolerated at high doses with minimal side effects.
Conclusions:
- AS ONs targeting PKC-alpha represent a promising strategy for cancer treatment due to their specificity.
- Further clinical evaluation is necessary to determine the therapeutic benefit of AS ONs in cancer patients, alone or in combination therapy.